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Available online 24 June 2016Background: Previously, we examined the difference in stent designs across different sizes for six widely used
Drug Eluting Stents (DESs).
Although stent post-dilatation to larger diameter is commonly done, typically in the setting of long tapering
segment or left-main PCI, there is an increasing recognition that information with regard to the different stent
model designs has a critical impact on overexpansion results.
This study aims to provide an update on stent model designs for contemporary DES platforms as well as test
overexpansion results under with oversized post-dilatation.
Methods and results:We studied 6 different contemporary commercially available DES platforms: Synergy, Xience
Xpedition, Ultimaster, Orsiro, Resolute Onyx and Biomatrix Alpha. We investigated for each platform the difference
in stent designs across different sizes and results obtained after post-expansion with larger balloon sizes. The
stents were deployed at nominal diameter and subsequently over expanded using increasingly large post
dilatation balloon sizes (4.0, 5.0 and 6.0 mm at 14ATM). Light microscopy was used to measure the changes in
stent geometry and lumen diameter after over-expansion.
For each respective DES platform, theMLD observed after overexpansion of the largest stent size available with a
6.0 mm balloonwas 5.7 mm for Synergy, 5.6 mm for Xience, 5.2 mm for Orsiro, 5.8 mm for Ultimaster, 5.5 mm for
4 mm Onyx (5.9 mm for the 5 mm XL size) and 5.8 mm for BioMatrix Chroma.
Conclusion: This update presents valuable novel insights that may be helpful for careful selection of stent size for
contemporaryDES based onmodel designs. Such information is especially critical in leftmain bifurcation stenosis
treatment where overexpansion to larger oversized diameter may be required to ensure full stent apposition.






DESs are nowadays commonly used in PCI for treatment of left-main
and long bifurcated segments. Due to the difference in lumen diameter
between the vessel and the stent size in some coronary arteries,
proximal post-expansion of the stent is normally necessary to match
proximal reference diameter and optimize stent apposition.
As stent post-dilatation is commonly performed, typically with large
over-expansion in the setting of long tapering vessel segment, there isore, 5 Hospital Drive, 169609,
land Ltd. This is an open access articlan increasing recognition that information with regard to the different
stentmodel designs can have a critical impact on overexpansion results.
Incomplete stent apposition has been associated with increased risk
of in stent restenosis (ISR) and stent thrombosis (1). Previously, we
examined the difference in stent designs across different sizes for 6
widely used Drug Eluting Stents (DESs) (2).
We tested overexpansion capacity of each stent design with post-
dilatation using balloon diameters up to 6 mm and showed how, in
absence of this critically important information, stents implanted in
segments with major changes in vessel diameter have the potential to
become grossly overstretched and to remain incompletely apposed
(2–4).
This study aims to provide an update on stent model designs for
contemporary DES platforms as well as test overexpansion results
under with oversized post-dilatation.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Stent design nomenclature
By convention, for DES platforms with only two designs, these were named here as
small vessel and large vesselmodel designs. For the Synergy platform which has three de-
signs, these were termed small, medium/workhorse and large vessel designs. It has to be
noted that this terminology was used for a uniform presentation in this manuscript and
manufacturersmay use a different nomenclature. A Crown or Peak is deﬁned as 2 adjacent
struts forming an angle. A complete stent Ring is formed by a number of adjacent crowns
which give the stent its expansion capacity from a crimping state. Rings are connected to
each other longitudinally by Connectors and a stent Cell is deﬁned as the area enclosed by a
pair of connectors and crowns (2).3. DES overexpansion experiments
Six commercially available drug-eluting stents (DESs) were
analysed: the everolimus-eluting PtCr SYNERGY™ (Boston Scientiﬁc,
Natick, MA, USA), everolimus-eluting Cobalt Chromium (CoCr)
XIENCE PRIME/XPEDITION™ (Abbott Vascular, Santa Clara, CA, USA),
the ULTIMASTER® - Drug eluting stent (Terumo Corporation, Shibuya-
ku, Tokyo, Japan), the ORSIRO Sirolimus Eluting Stent (BIOTRONIK AG,
Berlin, Germany), the Resolute ONYX™ Zotarolimus-Eluting Stent
(Medtronic, CA, US) and the BioMatrix Alpha/Chroma CoCr Stent
Platform (Biosensors Interventional Technologies, Singapore) (Fig. 2).
Samples of different stent sizes/models were deployed in vitro at
nominal pressure (NP). Subsequently, over-expansion results for each
design was tested with successive post-dilations using a 4.0 × 12 and
a 5.0 × 12 non-compliant balloons (Expected Diameter at 14 ATM =
5.02 mm) (NC Quantum Apex; Boston Scientiﬁc, Natick, MA, USA)
inﬂated at 14 ATM; for the largest designs, we used ﬁrst a 5.0 × 12
non-compliant balloon followed by a 6.0 × 15 mm semi-compliant
balloon (Maverick XL; Boston Scientiﬁc, Natick, MA, USA) with a
pressure of 14ATM (Expected Diameter at 14 ATM = 6.46 mm). Post-
dilation was performed on the proximal segment of the stent with a
stent length equivalent to length of the post-dilatation balloon. Final
dilations were repeated on the samples a second time to ensure an
optimal expansion of the stent struts. For each individual stent
diameter, two samples were deployed.4. Microscope analysis
Stent samples were mounted and analysed using light microscopy
(Leica MZ16 FA, Meyer Instruments, Houston, TX, USA). The magniﬁed
images of the stents were saved and used for quantitativemeasurement
and analysis of the deformation. Longitudinal and transverse sections of
the overexpanded stent at different reference in the proximal and distal
sections of the stents were compared to assess the differences after
overexpansion of the stents. Fig. 1 shows what parameters were
measured from each of the images.5. MLD and MSA
Cross-Sectional minimal lumen diameter was deﬁned as the
minimal lumen diameter (MLD) measured on the cross-sectional
images of the stent from one strut edge to the opposite strut edge. The
minimal stent area (MSA) was deﬁned to be the cross-sectional inner
lumen stent area excluding the stent struts. Lumen diameters were
also derived from the measured MSA to compare with the MLD values
measured from the cross sectional images.
On the proximal (over expanded) side, the lumen diameter was
measured both at the proximal edge of the stent aswell as 5mmdistally
from the proximal edge. Lumen diameter was also measured using the
side-view. Each measurement of MLD and MSA was repeated twice.
The result provided was an average of measures on two samples with
standard deviation.6. Cell opening
The change in cell openingwas estimated for each stent design after
beingdeployed at nominal pressure (NP) aswell as after overexpansion.
Cell opening was measured using the longitudinal view and was
estimated using a circle with its circumference ﬁtted within the stent
cell struts.
For a stent that has been ideally deployed in a vessel, the radius of
the circle ﬁtted within the cell represents the maximal distance
between the arterial tissue and a neighbouring stent strut. An average
of three measures was taken at NP and at maximal dilation (over
expanded). The maximal cell opening at maximal dilation was also
noted down and this occurs at the transition between the over expand-
ed stent portion and the stent portion at NP. To ensure that themaximal
dilation at the transition was measured, the stent was reoriented to be
able to view the stent cells in the transition region.
7. Crown angle analysis
To study the effects of over expansion on strut deformation, the
longitudinal view was used to measure the angle between 2 adjacent
struts within a crown, avoiding crowns attached to a connector.
CrownAnglewasmeasured at NP and at over. An average of 3measures
was taken at NP and at post dilation (over expanded).
8. Results
8.1. Stent platforms and model designs
Of the six DES platforms investigated, four of them: Xience, Orsiro,
Ultimaster and BioMatrix A/Chroma had two designs to cover the entire
range of their diameter while Synergy has three designs and Onyx has
four designs. For Synergy, we tested stents with nominal diameters of
2.75, 3.0 and 4.0 mm. For Xience and BioMatrix A/Chroma, stents with
nominal diameters of 3.0 (SV Model) and 3.5 mm (LV Model) were
tested. For Orsiro and Ultimaster we tested stents with nominal
diameters of 3.0 and 4.0 mm. For Onyx, stents with nominal diameters
of 2.5, 3.0, 4.0 and 5.0 mm were tested. Details of each DES design can
be found in Table 1.
8.2. Maximal expansion capacity
Table 2 shows the obtained measurements of lumen diameter from
both the cross-sectional and longitudinal images. Most stents were able
to expandwell above their labelledmaximal stent diameter using larger
post-dilatation balloons. Achieved MLD (considering minimal inner
lumen obtained, excluding struts) after overexpansion was between
25% and 78% higher than the nominal stent diameter and average
increase was 56%.
MLD observed after overexpansion of small-vessel workhorse
(below 2.5 mm size) was 3.6 mm for Synergy and 3.3 mm for Onyx
after post-expansion with a maximal non-compliant balloon of
4.0 mm at 14 atm. For medium-vessel workhorse (3 mm diameter
stents), the MLD observed after overexpansion with a maximal non-
complaint 5.0 mm balloon at 14ATM was 4.2 mm for Synergy, 4.0 mm
for Xience, 4.0 mm for Orsiro, 4.3 mm for Ultimaster, 4.3 mm for Onyx
and 4.1 mm for Chroma. For large-vessel workhorse (4.0 mm diameter
stents, 3.5 mm for Chroma), the MLD observed after overexpansion
with a 6.0 mm semi compliant balloon at 14ATMwas 5.7mm for Syner-
gy, 5.6 mm for Xience, 5.2 mm for Orsiro, 5.8 mm for Ultimaster, 5.5 mm
forOnyx and 5.8mmforChroma. Additionally, we tested theOnyx extra-
large design which is available up to 5.0 mm size andMLD after overex-
pansion with 6.0 mm semi compliant balloon at 14ATM was 5.9 mm.
The LD derived from MSA also showed very good agreement with
direct LD measurement, with the maximum difference being 0.2 mm
(Table 2).
Fig. 1.Methods of Measurements: Minimal Lumen Diameter (MLD) is measured from the side view at the edge and 5 mm distal from the overexpanded edge (A). Cell opening diameter,
including a cell opening diameter at the stent transition (B) and crown angle (C) are also measured from the side view. From the cross-sectional view, the Stent Luminal Diameter on 2
perpendicular axis (D) and the minimal stent lumen Area (E) are also measured.
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Over expansion of stents are characterized by important strut
distortion and large cell enlargements depending on the stent structure
designs. Larger average distances between adjacent struts indicate large
gaps in strut scaffolding which increases the risk of plaque prolapsing
between struts, reducing drug delivery efﬁcacy per unit wall surface
area.
Diameter cell opening was assessed for each design and com-
pared between maximal expansion and nominal pressure deploy-
ment. For the different platform, cell opening varied based on
model design and largely increased after over expansion (Table 3
and Fig. 3).
For cell opening diameter at nominal pressure, the cell openings for
Synergy were 0.6, 0.8 and 0.8 mm for the small, medium and large
designs respectively, for Xience the cell openings were 1.1 and 0.9 mm
for the medium and large designs respectively, for Orsiro the cell
openings were 0.6 and 0.8 mm for the small and mid-large designs
respectively, for Ultimaster, the cell openings were 0.7 and 1.0 mm for
the small andmid-large designs respectively, forOnyx, the cell openings
were 0.9 mm for all diameters and for Chroma, the cell openings were
1.1 and 1.0 mm for the medium and large designs respectively.
Cell opening diameter increased by an average of 114% between
nominal pressure deployment and over expansion. The percentage in-
crease for Synergy was 150, 131 and 145% for the small, medium andlarge designs respectively, for Xience it was 48 and 83% for the medium
and large designs respectively, for Orsiro it was 164 and 145% for the
small and mid-large designs respectively, for Ultimaster it was 119 and
123% for the small and mid-large designs respectively, for Onyx it was
90, 107, 104 and 89% for the small, medium, large and extra-large
designs respectively and for Chroma it was 70 and 147% for themedium
and large designs respectively.
The largest cell opening diameter was generally observed in the
mid-section of the stent at the transition. For Synergy it was 1.5, 1.8
and 1.9 mm for the small, medium and large designs respectively, for
Xience it was 1.6 and 1.7 mm for the medium and large designs respec-
tively, for Orsiro it was 1.5 and 2.0 mm for the small and mid-large
designs respectively, for Ultimaster it was 1.6 and 2.2 mm for the small
and mid-large designs respectively, for Onyx it was 1.7, 1.8, 1.8 and
1.7mm for the small, medium, large and extra-large designs respective-
ly and for Chroma it was 1.8 and 2.5 mm for the medium and large
designs respectively.8.4. Crown deformations
Increasing the post-dilatation diameter causes the stent struts to
progressively straighten with some stent rings becoming almost
circular in the post-dilated segment as they approach their stretching
limit (Table 3 and Fig. 4).
Fig. 2. Largest workhorse designs for each stent platform: Each of the picture shows the longitudinal image as well as the cross sectional image of the largest workhorse design of each
platform after over expansion to 6.0 mm.
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angle from an average crown angle of 77 ± 8° across all stents at
nominal pressure deployment to 146 ± 15° after over expansion.
For the largest workhorse designs of all the platforms, Chroma
showed the largest percentage increase in crown angle at 151% while
Onyx on the other hand showed the smallest percentage increase in
crown angle at 50%.
9. Discussion
In this study, we tested the overexpansion capabilities from six
contemporary DES platforms, testing each design of each platform
using increasing balloon sizes. Light microscopy was used to assessthe morphological changes from nominal deployment to overexpan-
sion. The main ﬁndings show that:
• Newer DES designs have similar cut-off diameter between small and
large vessel size, and are able to expand largely beyond their nominal
diameter.
• Overexpansion not only increases the MLD and MSA, but also
increases the cell size and also the straightening of the struts.
• The morphological change in stent varies between stent platforms as
well as stent size (model design) for a given platform.
Although normally comprised between 4.5 and 5.0 mm, the average
diameter of a left main artery may reach over 5.5 mm in some patients
according to some recent imaging studies (5,6), which means most of
Fig. 3. Cell opening measurements at nominal pressure (NP) deployment and at over
expansion (OE): Cell opening values are the average values across 6 measurements.
Comparable cell opening values between the platforms and designs are observed at
nominal diameter. Overexpansion increased cell opening by more than two folds, which
is likely to affect scaffolding and drug delivery.
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anatomies (currently, only the Taxus and the Resolute Onyx XL are
provided in size above 4.5 mm). Other platforms will require post
dilatation of at least 0.5 mm beyond their nominal diameter to ensure
the optimal apposition of the stent in these anatomies (2,6,7).
We should note the fact that these DESs can be oversized does
not imply that it is safe to do so. Indeed approaching physical limit
of the stent induces changes in mechanical stiffness and drug deliv-
ery, therefore the performance of the device can be completely
altered.
To our knowledge, in the main stream DES platforms, only the large
size design of the Synergy (4.0 size), Promus Element (4.0 size),
Resolute Onyx XL (4.5 and 5.0 size) and Taxus (4.5 and 5.0 size, Boston
Scientiﬁc) have been labelled for post-expansion beyond 5.0 mm.
Malapposition of stents due to lack of incomplete stent expansion
has been known to be a predicator of adverse outcomes (8–10).
Although there is a need for overexpansion to treat left main stenosis,
data regarding overexpansion beyond labelled recommendation are
rarely provided by the manufacturers.Fig. 4. Crown Angle measurements at Nominal Pressure (NP) deployment and at Over
Expansion (OE): The crown angles are measured between adjacent struts that do not
have a connector between them. Although at nominal diameter crown angles usually
ranged from 63 to 95°, this was increased after overexpansion to over 122°, indicative of
how much straightening was present in the crowns after overexpansion.There have been previous studies done on stent over expansion. A
previous study from our group on overexpansion looked at six stent
platforms and their morphological changes after overexpansion (2).
This study aimed at applying a similar methodology to look at
contemporary DES platforms.
Kissing balloon technique was not investigated in this study. Several
experiments showed that Kissing balloon technique, which is common-
ly employed in bifurcation cases, may lead to severe elliptical stent
distortion and even malapposition in some case if used to optimize ap-
position of the entire proximal stent segment (11–14). A more circular
stent cross section is expected after Proximal Optimization Technique
(POT). Therefore POT is nowadays recommended not only to optimize
the stent before but also as a ﬁnal step if Simultaneous Kissing Balloon
is performed to correct the potential stent distortion caused by the
overlap of the 2 balloons (4,11–13,15).
10. Lumen diameter and minimal stent area
In this study, we can see that all stent designs were able to expand
well beyond nominal diameter. From the longitudinal measurements,
most stents show similar diameters between the proximal over expand-
ed edge and 5 mm distal from the proximal edge, indicating that the
stent expanded evenly length-wise. Cross sectional LD measurements
show that the MLD is within 0.1 mm of the average LD measured from
side-view. This indicates that the overexpansion was even and the
stent expanded uniformly.
The general consensus is that the stents should be sized based on the
distal diameter of the vessel, especially for bifurcations, using POT for
optimal apposition of the proximal side of the vessel (4). Although in
an ideal scenario, the stents should be able to achieve a MLD equal to
the diameter of the balloon, we see here that this is often not the case,
which is in accordance with other reports (1,2,6,16,17). For our study,
all large stent designs were post dilated using a 6.0 mm semi-
compliant Maverick balloon (Expected Diameter at 14 ATM =
6.46 mm) but the MLD obtained on the stents only ranged from
5.3 mm to 6.0 mm.
As the strut straightens, the hoop force that the balloon has to
provide to induce plastic deformation of the stent and limit elastic
stent recoil increases. An in-vivo study by Berrocal et al. observed
more stent recoil in overexpanded stents (18). Minimizing stent recoil
is important as it leads to lowered risk of restenosis (19). Another
study by Carrozza et al. suggested that an overexpansion of 10–20%
above the reference vessel diameter is necessary as a solution to
compensate the difference with compliance chart and optimize stent-
to-artery ratio (16).
Post-dilatation balloon applied to stents tend to achieve lesser
diameter enlargement than indicated by their post dilatation balloon
compliance chart. Nevertheless, all stent platforms here could achieve
with their largest design a MSA ranging from 22.2mm2 to 28.4 mm2
and a MLD ranging from 5.3 mm to 6.0 mm, which can accommodate
most left main anatomies.
It can also be observed that stent platforms with only two designs
are able to generally expand as much as stents with more designs,
indicating that only 2 stent designs does not necessary hinder the stent's
overexpansion capabilities.
11. Crown angle
It can be observed that overexpansion of the stents leads to a large
discrepancy in crown angles, with increase ranging from 50% up to a
151% increase in crown angles. Large crown angle N150° indicates that
the stent crowns are almost completely straightened and the stent is
reaching its physical limit. Overexpansion and straightening of crowns
is expected to be associated with increased radial force and stiffness.
Although increase in radial force is good, an increase in stiffness can
reduce the stent durability and get it more prone to fatigue and stent
Fig. 5. SEM analysis of DESs after nominal pressure (left) deployment and overexpansion (right): Stents shown in the table are the largest workhorse design for each platform. All stents
were ﬁrst post dilated using a 5mmNC balloon followed by overexpansionwith a 6.0mmSC balloon. Overexpansion causes visible straightening of the stent struts. Most coating resisted
well despite oversizing with only minor cracks on the coating appearing in the crowns when deformation was the most severe.
176 J. Ng et al. / International Journal of Cardiology 221 (2016) 171–179fracture (2). Recent bench studies have shown the impact of stent de-
signs and connectors on mechanical response, such as longitudinal
strength and bending fracture (20,21).
12. Cell opening diameter
Cell opening diameter increase during overexpansion also varies
largely depending on stent design: we observed a range up to 164%increase in cell opening diameter. This indicates an increase in cell size
during overexpansion and the distance between strut scaffolds, hence
increasing the risk of underlying plaque prolapse in between the struts.
The increased gap between strut scaffolding can also negatively affect
the drug eluting properties of the stent, potentially causing reduction
in drug elution in overexpanded regions and chance of neointimal
proliferation. A study done previously by Basalus et al. showed how
cell area of a partly overexpanded stents varied based on the location
Table 1
DES workhorse and model designs: This table shows the designs of stents for each platform and also the sizes covered for each design. Most DESs only use 2 designs to cover the entire
range of diameters, with the exception of Synergy and Resolute Onyx.
177J. Ng et al. / International Journal of Cardiology 221 (2016) 171–179of the cell and the larger cell opening was shown to be at the transition
region between the oversized and nominal segment (17). Although the
relationship between struts scaffolding and drug distribution per unit
area and the onset of restenosis is not known, careful stent selection
based on design model is important to minimize stent deformations
and risk of prolapse.
13. Drug coating integrity
Damage on the drug coating was not speciﬁcally looked at in this
study. Overexpansion subjects the stent strut and the coating toTable 2
Measured values of MSA and LD from cross-sectional and longitudinal images: The measureme
strut). Values obtained are the average of the measurement from 2 oversized samples for each










Synergy SV 2.75 5.0 3.6
WH 3.5 5.0 4.2
LV 4.0 6.0 5.7
Xience SV 3.0 5.0 4.0
LV 4.0 6.0 5.6
Orsiro SV 3.0 5.0 4.0
LV 4.0 6.0 5.2
Ultimaster SV 3.0 5.0 4.3
LV 4.0 6.0 5.8
Resolute Onyx SV 2.5 4.0 3.3
MV 3.0 5.0 4.3
LV 4.0 6.0 5.5
XL 5.0 6.0 5.9
BioMatrixA/Chroma SV 3.0 5.0 4.1
LV 4.0 6.0 5.8extreme forces and deformation (14), increasing the risk of polymer
coating damage. Other studies have addressed previously this point
(14) and it is important to realize that the drug coating can be affected
during severe over-expansion or Kissing Balloon technique. Drug
coating damages or detachment of debris may expose patients to
potential risks of thrombosis and inﬂammation with neointimal
reactions (22,23). In Fig. 5, scanning electron microscope (SEM) images
of each stent design at nominal pressure deployment as well as after
overexpansion show that, although some minor coating defects may
start to appear at the crowns which undergo the most severents are the minimal lumen diameter within the boundaries of the stent (not including the
stent design. Percentage change was calculated using the measurement values obtained
with a 6.0 mm semi-compliant balloon at 14ATM.







3.6 11.4 0.4 3.7 3.7 53
4.2 14.4 0.5 4.1 4.2 57
5.7 27.5 0.3 5.8 5.8 56
4.1 13.6 0.4 4.2 4.2 48
5.6 26.1 1.3 5.6 5.5 67
4.0 13.0 0.2 4.0 4.3 60
5.3 22.2 0.5 5.3 5.5 58
4.3 15.1 0.0 4.3 4.4 69
5.8 27.5 0.3 5.7 5.8 63
3.3 9.1 0.0 3.4 3.6 43
4.4 15.5 0.1 4.3 4.5 60
5.6 24.6 0.1 5.5 5.2 39
6.0 28.4 0.3 6.0 6.0 25
4.1 14.0 0.1 4.3 4.3 61
5.9 27.7 0.1 5.9 5.8 78
Table 3
Measured and derived cell opening and crown angle values and percentages: The percentage change in crown angle and cell opening varies based on the design used. Cell opening diam-
eters at the segment of the stent transition from the nominal deployment to the over expanded segment showed the largest cell opening diameters and are noted down as the maximal
transitional cell opening. The cell opening and crown angle values are obtained from the average of 6 measurements, 3 different locations per sample and 2 samples per stent design.




Crown angle (°) Cell opening (mm)
NP OE % Increase NP OE % Increase Maximal
transition OE
Synergy SV 2.75 5.0 82 167 103 0.6 1.5 150 1.7
WH 3.5 5.0 74 147 98 0.8 1.8 131 2.0
LV 4.0 6.0 80 157 97 0.8 1.9 145 2.2
Xience SV 3.0 5.0 79 156 97 1.1 1.6 48 1.8
LV 4.0 6.0 74 154 108 0.9 1.7 83 1.9
Orsiro SV 3.0 5.0 82 151 85 0.6 1.5 164 1.7
LV 4.0 6.0 95 157 65 0.8 2.0 145 2.2
Ultimaster SV 3.0 5.0 68 124 83 0.7 1.6 119 2.1
LV 4.0 6.0 68 131 93 1.0 2.2 123 3.0
Resolute Onyx SV 2.5 4.0 81 128 59 0.9 1.7 90 1.8
MV 3.0 5.0 72 126 76 0.9 1.8 107 2.1
LV 4.0 6.0 82 158 92 0.9 1.8 104 2.1
XL 5.0 6.0 81 122 50 0.9 1.7 89 1.8
BioMatrixA/Chroma SV 3.0 5.0 68 155 129 1.1 1.8 70 1.9
LV 4.0 6.0 63 159 151 1.0 2.5 147 2.6
178 J. Ng et al. / International Journal of Cardiology 221 (2016) 171–179deformation, stent coating resisted overall well for all the DESs during
oversizing.
14. Radial strength
As stent crowns straighten, the resulting radial force of the stent is
also expected to increase. Although not speciﬁcally looked at in this
study, overexpansion also increases stent stiffness due to the straight-
ening of the crown close to the stent physical limit (2,24). This may
increase risk of strut fracture due to metal fatigue on the stent.
Mechanical response and durability data on stents overexpanded
close to maximal expansion capacity are still lacking and need to be
evaluated further.
15. Limitations of study
• Measurements obtained from this study should be carefully
interpreted as the stents were deployed in vitrowithout the presence
of a constraining arterial wall to limit the expansion of the stent.
Hence, the results obtain are only an approximation of the actual
in vivo behaviour of the stent-artery response during overstretching
(25). Also, the hoop force the balloon has to overcome to induce
further stent deformation would be much higher in vivo due to the
presence of stiff ﬁbrotic plaque.
• In some design, increasing the diameter of the balloon used may
further straighten the struts and further expand the stents. The largest
maximal balloon diameter used in this study was 6.0 mm and the
dilatation pressure was limited to the Rated Burst Pressure (14
ATM), equivalent to a maximal balloon diameter of 6.46 mm. The
Inner MLD achieved on the stent large designs was inferior to this
balloon size by at least 0.5 mm.
• Both the radial strength and drug kinetics of stents were not sufﬁ-
ciently investigated in this study. As such, the key information on
the importance of stent oversizing alone does not allow for a complete
assessment of which stent is preferable.
16. Conclusion
Knowledge of the cut-off diameters between different stent models
has been previously shown to help in selecting the most suitable stent
size and hence help in the treatment of large bifurcation and left main
PCI. Careful selection of size according to contemporary DES modeldesignsmay help to avoid implanting stent sizes with too limited expan-
sion capacity which could result in malapposition and severe
overstretching of the stent.
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